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Summary. Background: Current manufacturing methods for
recombinanthumanfactor VIII(rFVIII)withinmammaliancell
cultures are ineﬃcient, hampering the production of suﬃcient
amounts for aﬀordable, worldwide treatment of hemophilia A.
However, rFVIII has been expressed at very high levels by the
transgenic mammary glands of mice, rabbits, sheep, and pigs.
Unfortunately, it is secreted into milk with low speciﬁc activity,
owing in part to the labile, heterodimeric structure that results
from furin processing of its B domain. Objectives: To express
biologically active rFVIII in themilk of transgenicmice through
targeted bioengineering.Methods: Transgenic mice were made
withamammary-speciﬁcFVIIIgene(226/N6)bioengineeredfor
eﬃcient expression and stability, encoding a protein containing
a B domain with no furin cleavage sites. 226/N6 was expressed
with and without von Willebrand factor (VWF). 226/N6 was
evaluated by ELISA, SDS-PAGE, western blot, and one-stage
and two-stage clotting assays. The hemostatic activity of
immunoaﬃnity-enriched226/N6was studied in vivoby infusion
intohemophilia Aknockoutmice.Resultsandconclusions:With
orwithout coexpressionofVWF,226/N6was secreted intomilk
as a biologically active single-chain molecule that retained high
speciﬁc activity, similar to therapeutic-gradeFVIII. 226/N6had
> 450-fold higher IU mL)1 than previously reported in cell
culture for rFVIII. 226/N6 exhibited similar binding to plasma-
derived VWF as therapeutic-grade rFVIII, and intravenous
infusion of transgenic 226/N6 corrected the bleeding phenotype
of hemophilia A mice. This provides proof-of-principle for the
study of expression of 226/N6 and perhaps other single-chain
bioengineered rFVIIIs in themilk of transgenic livestock.
Keywords: factor VIII, hemophilia, mammary gland, modiﬁed
B domain, recombinant protein, transgenic animal, von Wille-
brand factor.
Introduction
Hemophilia A is an X-linked, inherited disorder of blood
coagulation, primarily caused by deﬁciency or dysfunction of
factor VIII, that affects approximately one in every 5000–
10 000 males [1–3]. FVIII is present at only 100–200 ng mL)1
in blood plasma, and is a post-translationally complex, large
glycoprotein of about 260–280 kDa [4–6]. FVIII acts as an
essential cofactor for FIX in the coagulation cascade to amplify
the activation of FX> 1000-fold. The structural complexity of
FVIII [7] remains at the core of therapeutic problems such as
abundance and the frequently encountered inhibitory immune
responses to intravenous therapy. Thus, both the development
of universal prophylactic and non-intravenous, low-bioavail-
ability treatments in economically developed countries and
routine access in developing countries are precluded [1,8,9].
The biosynthesis and secretion of FVIII into blood plasma
by hepatocytes and recombinant FVIII (rFVIII) by mamma-
lian cells are greatly and similarly inefﬁcient, owing to
limitations in transcription [10–12], post-translational process-
ing, and translocation from the endoplasmic reticulum to the
Golgi apparatus [13,14]. The most biosynthetically restricted
rFVIII structure is the analog of native FVIII containing its
full-length (907 amino acids, 90 kDa) B domain (FL-rFVIII).
The B domain is processed by furin at two different sites,
leading to a complex mixture of labile [15], metal ion-stabilized
heterodimers (Fig. S1). Thus, all therapeutic-grade plasma-
derived FVIIIs (FL-FVIIIs) and FL-rFVIIIs are heterodimeric
and contain no single-chain species [7]. von Willebrand factor
(VWF) helps to stabilize the labile, heterodimeric structure of
both FL-FVIII in the blood circulation and of FL-rFVIII in
cell culture media. Although VWF does not increase the
expression levels of FL-rFVIII, the presence of VWF in cell
culture media increases the accumulation of FVIII activity to
about 1–2 IU mL)1, which is about the same as in normal
human plasma [16].
We and others have previously reported high concentrations
of FL-rFVIII in themilk of transgenicmice [17], rabbits [18,19],
sheep [20], and pigs [21], showing that the mammary gland can
efﬁciently secrete rFVIII with a full-length B domain. How-
ever, the speciﬁc activity of the FL-rFVIII was very low, at
about 0–10% of expected levels (Table S1). The native
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appearance of the FL-rFVIII heavy and light chains found in
these milks suggested that the conformation of the assembled
heterodimer, and not necessarily proteolytic degradation, was
the main cause of the low activity in milk (Fig. S2) [21].
Unlike previous studies, in which FL-rFVIII was expressed
in milk, in this study we expressed a bioengineered rFVIII with
a modiﬁed B domain (226/N6) having no furin sites in the
presence and absence of the potentially stabilizing inﬂuence of
recombinant VWF (rVWF) coexpressed in mouse milk. The
consensus sites for furin cleavage at Arg1313 andArg1648 were
removed by truncating the B domain to the ﬁrst 226 amino
acids (Fig. S1B). We provide the ﬁrst report of rFVIII made at
high levels in transgenic milk with native procoagulant activity.
Materials and methods
All animal procedures were approved by the Institutional
Animal Care and Use Committee at the University of
Michigan and Virginia Polytechnic Institute and State Univer-
sity.
DNA constructs
The 226/N6 (WAP7FVIII-226/N6) construct was assembled
by altering the KpnI site of pUCWAP6 [22] by introducing a
SalI site immediately downstream of the 4.1-kbp whey acidic
protein (WAP) promoter and ahead of the 1.7 kbp of mouse
WAP 3¢-untranslated region (UTR) containing the coding
sequence for the polyadenylation signal to produce pUC-
WAP7. The sequence for FVIII-226/N6 was removed by
restriction enzyme digestion with SalI and XhoI from pMT2
226/N6, as described previously [14], and introduced into the
SalI site of pUCWAP7, yielding the pUCWAP7FVIII-226/N6
plasmid. The plasmid pUCWAP6VWF containing the
WAP6VWF expression construct (gift from H. Lubon, Amer-
ican Red Cross, Rockville, MD, USA) contained the cDNA
for VWF placed between the 4.1-kbp WAP promoter and the
1.7-kbp 3¢-UTR. The plasmid designated PPL456, containing
the b-lactoglobulin (BLG)-driven a1-antitrypsin (AAT) con-
struct, which has been previously described [23], was a gift from
D. Ayares (Revivicor, Blacksburg, VA, USA). The WAP7F-
VIII-226/N6 was released by NotI. The WAP6VWF was
released by digestion with NotI and SﬁI. The BLG-AAT was
released by digestion with NotI and SalI. All constructs were
puriﬁed by extraction prior tomicroinjectionwith aNucleospin
Extract kit (Clonetech Laboratories, Palo Alto, CA, USA).
Transgenic mouse generation, identification, and milk
collection
Transgenic mice were generated by pronuclear microinjection
of puriﬁed DNA constructs, as previously described [24], at the
Transgenic Core facility at the University of Michigan.
Southern blot analysis was performed as previously described
[21]. PCR probes (KPL, Gaithersburg, MD, USA) are shown
in Fig. S3A. The primers for 500 base pair PCR products were:
for WAP, WAPprobeS1 (gcatgctcacactcaacagg)/WAPprobe-
A1 (taagagtgtggaggcgcttg); and for AAT, the same primers as
for PCR, BLG-S1/AAT-A1. Milk was collected and defatted
as previously described [24]. Samples were stored at ) 70 C.
FVIII biochemical analysis
FVIII activity was measured with a one-stage activated partial
thromboplastin time (APTT) clotting assay on an MLA
Electra 750 ﬁbrinometer by reconstituting human FVIII-deﬁ-
cient plasma (George King Bio-Medical, Overland Park, KS,
USA), and a modiﬁed two-stage assay utilizing the COA-
MATIC Factor VIII (Chromogenix, Milan, Italy), according
to the manufacturers instructions. FVIII antigen levels were
determined with an ELISA kit (Afﬁnity Biologicals, Ancaster,
ON, Canada), on the assumption of an FVIII concentration of
200 ng mL)1 per 1 IU mL)1 of activity (5000 IU mg)1);
1 IU mL)1 is the deﬁned concentration of FVIII activity in
normal human plasma, which contains an average concentra-
tion of 100–200 ng mL)1.
Immunoaffinity chromatography (IAC) enrichment of 226/N6
Defatted milk was diluted and incubated overnight with anti-
heavy chain FVIII monoclonal antibody-conjugated sepharose
beads (kindly provided by Baxter BioScience, Deerﬁeld, IL,
USA). The enrichment procedure was carried according to the
protocol described previously [25], with and without wash steps
with 250 mM CaCl2 and MgCl2 to disrupt FVIII:VWF
complexes [26] prior to elution of FVIII. One milligram per
milliliter of AAT was added as a stabilizer after IAC
enrichment. 226/N6 from CHO cells was enriched from stably
transfected CHO cell lines as described previously [14].
Immunoblotting
Non-reduced and reduced samples were evaluated by SDS-
PAGE on 4–12% NuPage Bis-Tris gels (Invitrogen Carlsbad,
CA, USA), and then electroblotted onto poly(vinylidene
ﬂuoride) membranes (Millipore, Billerica, MA, USA). Blots
were probed with polyclonal antibodies against FVIII (F0016-
10; US Biological, Swampscott, MA, USA), VWF (V2700-
04B; US Biological), or AAT (A2298-27H; US Biological).
FVIII–VWF binding ELISA
226/N6 and rFVIII (Advate; gift from Baxter) were incubated
with 1% FVIII-deﬁcient human plasma (George King Bio-
Medical). Triplicate samples were incubated with an anti-FVIII
antibody (BO2C11; gift from M. Jacquemin, University of
Leuven, Belgium) that inhibits VWF binding [27] prior to
incubation with 1% FVIII-deﬁcient human plasma. Samples
were loaded into 96-well plates precoated with anti-FVIII
antibody (F8C-EIA-C; Afﬁnity Biologicals). Anti-VWF anti-
body (p0266; Dako, Carpenteria, CA,USA) was used to detect
VWF binding. Absorbance was read at 490 nm.
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In vivo tail clip assay in hemophilia A (HA) mice
HA exon 16 knockout mice [28] were subjected to a tail clip
bleeding assay.Mice at least 10 weeks of age were injected with
IAC-enriched FVIII proteins. C57BL/6 and HA mouse
littermates were used as controls for injection with lactated
Ringers (LR) solution. Mice were injected with 80 IU kg)1
body weight of FVIII in 100 lL LR solution via the tail vein.
Ketamine 85 mg kg)1 with xylazine 5 mg kg)1 was injected
intraperitoneally to induce anesthesia. After 5 min, tails were
cut at 1.5-mm diameter from tail tips, and then immediately
submerged in 14-mL conical tubes ﬁlled with saline at 37 C.
Blood from the tail was collected at 10 min. Blood loss was
quantiﬁed by the difference in tube weight between time 0 and
10 min. Mice were then killed.
Statistical analysis
Data are presented as mean ± standard deviation, except for
bleeding data, which are presented as median ± standard
deviation. A single-factor analysis of variance (ANOVA) was
performed to compare blood loss results. Students t-tests (two-
tailed), assuming unequal variances, were used to compare
each treatment group with control mice. An alpha level of 0.05
was used for all statistical analysis.
Results
Production and selection of transgenic mice
by expression level
We made monogenic and bigenic 226/N6 mice with three
different transgenes (Fig. S3) to help test the following
hypotheses: (i) single-chain rFVIII would be expressed at a
range of concentrations inmilk similar to or higher than that of
FL-rFVIII; (ii) coexpressed rVWFwould complex 226/N6 and
help stabilize single-chain rFVIII made in milk, as it does in
plasma and cell culture; and (iii) single-chain rFVIII would
have higher speciﬁc activity than FL-rFVIII when expressed in
milk. An optimized BLG-AAT gene was used to make lineages
of bigenic and trigenic 226/N6 mice in an effort to mitigate
transcriptional silencing, which occurs in > 60% of cases of
mammary expression in transgenic mice. Silencing was
decreased to about 25% in mice coinjected with the BLG-
AAT transgene [29,30]. Twenty different potential founder
animal litters were made by outbreeding with control animals.
Transgenic mice maintained a natural lactation length of about
17 days, and had normal litter growth. About 50–100 lL of
milk was obtained per milking.
Detectable levels of rFVIII and activity were present in some
mice monogenic for 226/N6 alone, whereas no rFVIII protein
or activity was detected in milk from mice bigenic for 226/N6
and rVWF (Table 1). In the presence of the BLG-AAT milk
gene, both the level and activity of 226/N6 were much higher
for bigenic (226/N6 and BLG-AAT) and trigenic (226/N6,
rVWF, and BLG-AAT) lineages than for monogenic 226/N6
mice. For these bigenic and trigenic mice containing the BLG-
AAT gene, AAT was expressed at > 1 mg mL)1 (Fig. S4). In
summary, whereas transgene silencing probably occurred in
some lineages, the concentration range of 226/N6 found in the
milk of all mice was similar to previously reported concentra-
tion ranges for FL-rFVIII made in the milk of mice, rabbits,
sheep, and pigs, with the highest concentration of 226/N6 being
about 0.2–0.3 mg mL)1.
Specific clotting activity and analysis by western blot
We studied the transgenic mice with the highest 226/N6 protein
expression levels and expanded those lineages. The speciﬁc
activity was determined directly in the whole milk pools by
measurement of FVIII antigen by ELISA and coagulation
activity by APTT assay (Table 1). Notably, the 226/N6 speciﬁc
activities found in the milk from monogenic, bigenic and
trigenic mice were all similar and typical of plasma-derived
FVIII or FL-rFVIII. Importantly, 226/N6 was also functional
without the presence of AAT or rVWF. Because there are few
high molecular mass proteins in the milk of mice near or at the
molecular mass of 226/N6 or VWF under reducing conditions,
quantitative western blotting was possible. The high 226/N6
levels determined by ELISA were conﬁrmed by quantitative
western blot analysis under reducing conditions (Fig. S5).
Table 1 The speciﬁc activity of 226/N6 in milk
Mouse genotype,
mouse ID
226/N6
concentration
(lg mL)1)
APTT
activity level
(IU mL)1)
Speciﬁc
activity
(IU mg)
Monogenic
mice: 226/N6
1960-1702 0.144 0.6 4.167
1926-1742 0.093 0.1 1.075
46-1247 0.066 0.4 6.061
Bigenic mice:
226/N6-rVWF
376-8 Not detected Not detected
376-12 Not detected Not detected
383-49 Not detected Not detected
Bigenic mice:
226/N6-BLG-AAT
875-234 34 25 735
875-233 6.2 44 7.097
516-46 7.3 13 1.781
406-128-10 83 122 1.470
Trigenic mice:
226/N6-rVWF-BLG-AAT
415-101-2 183 678 3.705
415-101-1–2 122 555 4.549
AAT, a1-antitrypsin; APTT, activated partial thromboplastin time;
BLG, b-lactoglobulin; rVWF, recombinant von Willebrand factor.
1 IU mL)1 is the deﬁned concentration of FVIII activity in normal
human plasma. An average concentration of 200 ng mL–1 per mL of
normal human plasma is assumed, yielding a theoretical speciﬁc
activity of 5000 IU mg)1.
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Interactions of 226/N6 with rVWF and VWF
Strong interactions between VWF and FVIII result from
conformations stabilized by intramolecular disulﬁde bonding
within FVIII andVWF subunits. The interactions between FL-
FVIII and VWF in therapeutic-grade preparations are not
appreciably destabilized by treatment with SDS under non-
reducing conditions, as shown by the decreasedmobility seen in
western blot analysis (Fig. 1). Reducing conditions destabilize
these binding interactions, resulting in greater mobility that is
commensurate with the molecular size of FVIII and VWF
monomers, respectively. In contrast, puriﬁed preparations of
therapeutic-grade FVIII containing no VWF do not show the
greatly decreased electrophoretic mobility in SDS-PAGE
under non-reducing or reducing conditions. This intramolec-
ular disulﬁde bridge-dependent phenomenon occurring within
the VWF and FVIII molecules was used to help determine the
extent of 226/N6 complexation with rVWF in milk. The
electrophoretic migration of heterodimers under reducing and
non-reducing conditions for therapeutic-grade FL-rFVIII
made in CHO cells not containing VWF was similar. The
molecular mass of the heterodimers was consistent with the
published range of 100–220 kDa (Fig. 1A,B), although they
possessed no signal for VWF (Fig. 1C,D).
A trigenic (226/N6, rVWF, and BLG-AAT) mouse milk
pool containing 300 lg mL)1 of both 226/N6 and rVWF
showed a single predominant FVIII signal at about 190 kDa
under reducing conditions. The VWF signal had a similar
molecular mass (about 320 kDa) as the plasma-derived
FVIII:VWF reference under reducing conditions. Importantly,
the same shift to a retarded migration of molecular mass
> 420 kDa occurred for the trigenic sample under non-
reducing conditions as occurred with the plasma-derived
FVIII:VWF complex. Bigenic mouse milk containing no
rVWFmigrated similarly to the trigenic sample under reducing
conditions, but did not exhibit the greatly retarded migration
under non-reducing conditions. These results show that 226/N6
was secreted as a single chain into milk with or without VWF.
IAC was applied to a whey phase made from centrifugally
clariﬁed and diluted trigenic mouse milk to provide an
infusable preparation enriched in 226/N6 (Fig. 2). The IAC
captures FVIII and FVIII:VWF complexes. Trigenic milk was
subjected to IAC with loading and wash conditions under
which VWF:FVIII complexes were unstable, allowing most of
the VWF to be efﬁciently released before and during immu-
nosorption of 226/N6. Whereas the starting milk contained a
1 : 1 ratio of rVWF to 226/N6, IAC enrichment reduced the
stoichiometric ratio of rVWF to 226/N6 in the FVIII eluate to
about 0.1. The yield of 226/N6 from trigenic milk containing
high levels of 226/N6 was 10%, with an enrichment of 70-fold,
and a purity of 39% before addition of AAT for storage. This
IAC preparation was similar to an IAC-enriched therapeutic-
grade FL-rFVIII made from Recombinate (Table 2). Impor-
tantly, the speciﬁc activity of the IAC-enriched 226/N6 from
trigenic milk was similar to that of the 226/N6 from the original
milk and also the FL-FVIII and FL-rFVIII references
(Table S2).
IAC was also applied to milk from low-expressing animals
that did not coexpress VWF. Although the purity was < 1%
(Fig. S6), an enrichment of 16-fold was achieved for 226/N6 at
a similar speciﬁc activity to that found in the original milk
(Table 2). The yield of 226/N6 captured from milk containing
226/N6:VWF complexes was lower than the yields from non-
VWF-expressing milk.
Using ELISA, we studied the complexation of human
plasma-derived VWF with 226/N6 that could occur in FVIII-
deﬁcient plasma derived from a severe HA donor.We used this
model to determine whether 226/N6:VWF complexes would
form in a context more pertinent to future HA treatment. The
IAC-enriched 226/N6 preparations and therapeutic-grade FL-
rFVIII were immunocaptured on a microtiter plate. The
immobilized anti-FVIII monoclonal antibody has been shown
not to interfere with VWF binding. The presence of VWF
bound to the immunocaptured 226/N6 was detected with an
anti-VWF polyclonal antibody. To determine the speciﬁcity of
the interaction between 226/N6 and VWF in blood plasma, we
preincubated each immunocaptured rFVIII species with and
without a monoclonal antibody (B02C11) that binds to the
light chain of FVIII, inhibiting FVIII:VWF complexation [27].
In all cases, B02C11 inhibited the VWF signal arising from
incubation in plasma to low background levels. Without
pretreatment with B02C11, both immunocaptured FL-rFVIII
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Fig. 1. SDS-PAGE of FL-rFVIII and milk-borne 226/N6 in the presence
and absence of von Willebrand factor (VWF) under reducing and
non-reducing conditions. Assessment of VWF binding by (A) reduced
anti-FVIII, (B) non-reduced anti-FVIII, (C) reduced anti-VWF, and (D)
non-reduced anti-VWF SDS-PAGE western blots. All blots contain a
molecular mass marker. FL-rFVIII, recombinant FVIII; FVIII:VWF,
plasma-derived FVIII:VWF concentrate; 226/N6:rVWF milk, diluted
trigenic mouse milk equivalent to 0.07 lL of undilutedmilk; Control milk,
diluted non-transgenic mouse milk equivalent to 0.07 lL of undiluted
milk; 226/N6 milk, diluted bigenic mouse milk equivalent to 0.07 lL of
undiluted milk. Arrows indicate primary single-chain 226/N6 species.
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and 226/N6 exhibited strong VWF binding signals in a similar
dose-dependent fashion (Fig. 3). The similar polynomial ﬁts to
each of these absorption proﬁles indicated that FL-rFVIII and
226/N6 have similar avidities for VWF in human plasma.
Hemostatic potential of infused IAC-enriched 226/N6
We studied the hemostatic efﬁcacy of 226/N6 in vivo by using a
terminal tail transection bleeding model in HA mice. Figure 4
shows themedian total blood loss observed for normal C57/BL
miceandFVIIIknockoutHAmice resulting fromaterminal tail
transection. TheHAmice were infused with LR solution, IAC-
enriched 226/N6 made in CHO cells, or IAC-enriched 226/N6
frommilk. 226/N6 fromCHOcells and 226/N6 from transgenic
milk were each infused at 80 IU kg)1 body weight. Normal
C57/BL mice showed a cessation of bleeding (four of four) at
about 2–5 min, with the total weight of blood loss over 10 min
ranging from 80 to 165 mg. HAmice infused with LR solution
typically didnot showa cessationof bleeding (10of 12),with the
totalweight of blood loss ranging from115 to 725 mg.HAmice
infused with 226/N6 from CHO cells showed a cessation of
bleeding (ﬁve of ﬁve) at about 2–5 min, with the total weight of
blood loss ranging from 60 to 230 mg. HA mice infused with
226/N6 from transgenic milk showed a cessation of bleeding
(ﬁve of six) typically at about 2–5 min, withmostmice having a
total weight of blood loss ranging from 10 to 175 mg. Post hoc
analysis (two-tailed t-tests) showedthatLRsolution-treatedHA
mice bled signiﬁcantly more than LR solution-treated C57/BL
mice (P £ 0.001, a = 0.05), whereas both 226/N6 from CHO
cells and 226/N6 from transgenic milk-treated HA mice had
similar blood losses as LR solution-treated C57/BL mice
(P = 0.574 and P = 0.491, respectively, a = 0.05).
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Fig. 2. SDS-PAGE of immunoaﬃnity chromatography (IAC)-enriched 226/N6. 226/N6 and recombinant von Willebrand factor (rVWF) were IAC-
enriched from transgenicmousemilk and separatedduring the enrichment process. Enrichment of the 226/N6and rVWFwasperformedon clariﬁed, diluted
milk pooled fromsixF3 trigenicmice from the 415-101-2 line, andanalyzedby reducingSDS-PAGE(A) andanti-FVIII (B) andanti-VWF(C)westernblots.
The SDS-PAGE gel (A) contains amolecularmassmarker, an FVIII reference (FL-rFVIII; recombinate), a VWF reference (VWF), diluted non-transgenic
mousemilk equivalent to0.07 lLofundilutedmilk (Controlmilk), diluted trigenicmousemilk equivalent to0.07 lLofundilutedmilk (226/N6:rVWFmilk),
and trigenic milk product enriched by IAC (IAC eluate). The enriched 226/N6 is shown by the closed arrow ( ). The open arrow ( ) points to the
a1-antitrypsin (AAT) that was added at 1 mg mL
)1 to the IAC eluate for storage formulation. Each blot (B and C) contains a molecular mass marker,
a reference (FL-rFVIII and/or VWF), trigenic transgenic mouse milk (226/N6:rVWFmilk), and IAC-enriched trigenic milk product (IAC eluate).
Table 2 The speciﬁc activity of immunoaﬃnity chromatography (IAC)-enriched 226/N6 from clariﬁed, diluted milk
Sample
Total protein
(mg mL)1)
FVIII antigen
(lg mL)1)*
FVIII activity
(IU mL)1)
One-stage
activity level (IU mg)1)
%
Purity
% Antigen
yield
IAC
enrichment
Therapeutic-grade FL-rFVIII
(Recombinate)
21.95 ± 3.57 26.35 ± 2.64 90.09 ± 9.22 3.419 ± 634 < 1 NA NA
IAC-enriched FL-rFVIII
(Recombinate)
0.08 ± 0.13 35.58 ± 0.71 75.84 ± 2.18 2.132 ± 112 44 96 367-fold
IAC-enriched 226/N6
(bigenic milk)
0.66 ± 0.25 6.34 ± 0.64 22.10 ± 1.10 2.506 ± 267 < 1 63 16-fold
IAC-enriched 226/N6
(trigenic milk)
0.03 ± 0.01 10.32 ± 1.92 43.21 ± 2.75 4.187 ± 1.425 39 10 70-fold
NA, not applicable; rFVIII, recombinant factor VIII. *Determined by ELISA. Determined by activated partial thromboplastin time (APTT).
IAC enriched Recombinate used as a control. IAC enrichment calculated from FVIII antigen to total protein ratio.
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Discussion
The production of rFVIII in themilk of transgenic livestock is a
promising approach to signiﬁcantly increase the availability of
rFVIII therapy. Producing more rFVIII will help to advance
immunotolerance and non-intravenous therapy [31,32]. To-
wards that goal, our previous work and the work of others
showed that FL-rFVIII was efﬁciently secreted into milk at
10–1000-fold higher concentrations than are seen in blood
plasma or cell culture (Table S1). However, the speciﬁc activity
of the FL-rFVIII was very low. The broad range of FL-rFVIII
levels expressed in milk is probably caused by transcriptional
inefﬁciency, which often occurs as a result of transgene
integration into less transcriptionally active chromosomal sites
[29,30]. In founder lineages with favorable integration sites for
expression, this work shows that 226/N6 can be made at high
concentrations, similar to that ofFL-rFVIII.Therefore, 226/N6
is at least as efﬁciently secreted by the mammary gland as FL-
rFVIII, and additional improvements in transcriptional efﬁ-
ciency might enable even higher levels to be obtained. The 226/
N6,whichhas amodiﬁedB domain lacking furin sites, yieldeda
speciﬁc activity similar to that of therapeutic-grade reference
FL-FVIII and FL-rFVIII. Importantly, the infusion of IAC-
enriched 226/N6 from milk or CHO cells corrected the
hemostatic defect of FVIII knockout mice caused by a tail
transection trauma challenge.
Coexpressed AAT did not appear to impact on the speciﬁc
activity of the milk-borne 226/N6, as the speciﬁc activities of
226/N6 produced bymonogenic, bigenic and trigenicmice were
similar. AAT was added to enriched preparations to inhibit
plasmin generation during storage, because plasmin is a
naturally occurring, broadly acting protease in milk [33,34].
The general coexpression of milk protease inhibitors in order to
protect the recombinant protein product is still a future
developmental goal.
This is the ﬁrst report of any rFVIII being coexpressed inmilk
with rVWF. FVIII circulates as a complex with VWF that is
a prerequisite for its stability and thus its survival in the
circulation [13,35]. Therapeutic-gradeFL-FVIII:VWFcomplex
and 226/N6 in the presence of coexpressed rVWF had similarly
reduced electrophoretic mobilities. This, in addition to the
similar in vitro binding of plasma-derived VWF by 226/N6,
suggests that coexpressed VWF:226/N6 complexes existed in
the milk. The native binding of 226/N6 with plasma-derived
VWF indirectly shows that the proper post-translational
sulfation of Tyr1680 in the A3 domain of 226/N6 probably
occurred, as it is required for complexation [36]. 226/N6
expressed with and without rVWF in milk had > 450-fold
higher activity levels than the analogous bioreactor-produced
FL-rFVIII and > 40-fold higher activity levels than 226/N6
expressed in CHO cell culture without rVWF [14]. The high
activity levels accumulating in the milk in the presence or
absence of rVWF probably reﬂect the inherent stability of 226/
N6. This contrasts with the beneﬁcial effects of VWF coex-
pressed in cell culture, which stabilizes FL-rFVIII and increases
its accumulatedactivity levels [13,15,16]. This studyprovides the
ﬁrst proof that VWF binds to this 226/N6 design and that a
coexpressed FVIII:VWF product may be feasible in milk.
We acknowledge that the utilization of a bioengineered
rFVIII could result in neoantigenicity; however, the advantage
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of the 226/N6 design is that its bioengineering strategy targets
modiﬁcations to the B domain, where inhibitor antibodies have
infrequently been described. In addition, after thrombin
activation, 226/N6 assumes an active FVIII structure that is
identical to full-length wild-type FVIII [14]. There is also
evidence that VWF complexation with FVIII increases the
effectiveness of immune tolerance therapy [37]. Thus, the ability
of 226/N6 to complex with coexpressed rVWF and plasma-
derived VWF may be a beneﬁcial attribute in the development
of future applications of transgenically produced rFVIII.
The safety and efﬁcacy of transgenic milk-derived products
has crossed an important threshold, as the US Food and Drug
Administration and European Medicines Agency have ap-
proved recombinant anti-thrombin III made in goat milk
(ATryn, GTC Biotherapeutics, Framingham, MA, USA) [38].
Our study in mice provides the fundamental understanding
needed for the future expression of biologically active, single-
chain rFVIII molecules of different designs in the milk of
livestock. Pigs are a likely choice of transgenic livestock for
future production of rFVIII [32], because they combine the
advantages of milk volume and hepatocyte-like post-transla-
tional biochemistry, such as glycosylation [39]. With respect to
226/N6, which retains six of the 19 potential glycosylation sites
in the B domain, the glycosylation may impact on pharmaco-
kinetics. Although ruminants also provide an ample milk
volume, their mammary biochemistry produces higher-man-
nose, low sialic acid glycoforms that may affect circulation
residence times, owing to interactions with asialyo receptors
found in the human liver [40]. Given the fundamental
knowledge about rFVIII stability provided by our studies in
mice and pigs, we have begun to make transgenic pigs with
various modiﬁed B domain FVIII constructions. In contrast to
mice, the amount of rFVIII that will be produced in pig milk
will permit bioengineering studies on puriﬁcation and formu-
lation. The advantage of pig milk over other FVIII sources,
such as cell culture bioreactors and human plasma, is evident in
the greater than two orders of magnitude reduction in source
volume estimated to be needed to meet global FVIII demand
[38] (Table S3).
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